Pharmacokinetics of indomethacin ester prodrugs: Gastrointestinal and hepatic toxicity and the hydrolytic capacity of various tissues in rats

Biological and Pharmaceutical Bulletin

Volumn 19, Issue 9, 1996, Pages 1178-1183

  Ogiso, Taro ^a   Iwaki, Masahiro ^a   Tanino, Tadatoshi ^a   Nagai, Terumi ^a   Ueda, Yuko ^a   Muraoka, Osamu ^a   Tanabe, Genzo ^a  

^a KINKI UNIVERSITY   (Japan)

Author keywords

ester prodrug; gastrointestinal irritation; hepatic toxicity; hydrolysis; pharmacokinetics; rat

Indexed keywords

INDOMETACIN; PRODRUG;

ANIMAL EXPERIMENT; ARTICLE; DRUG EFFECT; DRUG HYDROLYSIS; INTESTINE MUCOSA; INTESTINE ULCER; INTRAVENOUS DRUG ADMINISTRATION; LIVER MICROSOME METABOLISM; LIVER TOXICITY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; STOMACH ULCER; TOXICITY TESTING; ULCEROGENESIS;

EID: 0029804639     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.19.1178     Document Type: Article

References (27)

1. Jennings G. H., Gut, 6, 1-13 (1965).
2. Rainsford K. D., Agents Actions, 5, 326-344 (1975).
3. Pemberton R. E., Strand L. J., Dig. Dis. Sci., 24, 53-61 (1979).
4. Jones G., "Design of Prodrugs," ed. by Bundgaard H., Elsevier, Amsterdam, 1985, pp. 199-241.
5. Cioli V., Putzolu S., Rossi V., Barcellona P. S., Corradino C., Toxicol. Appl. Pharmacol., 50, 283-289 (1979).
6. Shanbhag V. R., Crider A. M., Gokhale R., Harpalani A., Dick R. M., J. Pharm. Sci., 81, 149-154 (1992).
7. deCaprariis P., Palagiano F., Bonina F., Montenegro L., D'Amico M., Ross F., J. Pharm. Sci., 83, 1578-1581 (1994).
8. Arita T., Miyazaki K., Kohri N., Saitoh H., Yakugaku Zasshi, 105, 477-483 (1982).
9. Elsom L. F., Chasseaud L. F., Ray J., Hawkins D. R., Arzneim. Forsch./Drug Research, 29II, 1155-1160 (1979).
10. Brodie D. A., Cook P. G., Bauer J., Dagle G. E., Toxicol. Appl. Pharmacol., 17, 615-624 (1970).
11. Whitehouse M. W., Rainsford K. D., J. Pharm. Pharmacol., 32, 795-796 (1980).
12. Bundgaard H., Nielsen N. M., Int. J. Pharmaceut, 43, 101-110 (1988).
13. Mishima M., Kobayashi S., Abe S., Yamamoto C., Xenobiotica, 20, 135-146 (1990).
14. Ito R., Takahashi R., Honda N. (ed.), "A Collection of Animal Models Intended for Utilization in the Development of Novel Drugs," R & D Planning, Tokyo, 1985, pp. 247-254.
15. Omura T., Sato R., J. Biol. Chem., 239, 2370-2378 (1964).
16. Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J., J. Biol. Chem., 193, 265-275 (1951).
17. Ikeda M., J. Biochem. (Tokyo), 55, 231-243 (1964).
18. Kwong E., Pillai G. K., McErlane K. M., J. Pharm. Sci., 71, 828-830 (1982).
19. Ogiso T., Iwaki M., Kinoshita T., Tanino T., Paku T., J. Pharm. Sci., 83, 34-37 (1994).
20. Yamaoka K., Tanigawara T., Nakagawa T., Uno T., J. Pharmacobio-Dyn., 4, 879-885 (1981).
21. Gibaldi M., Perrier D. (ed.), "Pharmacokinetics," 2nd ed., Marcel Dekker, New York and Basel, 1982, pp. 84-111; idem, ibid., pp. 409-417.
22. Gibaldi M., Perrier D. (ed.), "Pharmacokinetics," 2nd ed., Marcel Dekker, New York and Basel, 1982, pp. 84-111; idem, ibid., pp. 409-417.
23. Vukoson M. B., Greiner J. W., Kramer R. E., Colby H. D., Biochem. Pharmacol., 27, 1977-1979 (1978).
24. Ogiso T., Iwaki M., Tamaki E., J. Pharmacobio-Dyn., 6, 803-813 (1983).
25. Burke M. D., Falzon M., Milton A. S., Biochem. Pharmacol., 32, 389-397 (1983).
26. Falzon M., Nielsch A., Burke D., Biochem. Pharmacol., 35, 4019-4024 (1986).
27. Nielsen N. M., Bundgaard H., J. Pharm. Sci., 77, 285-298 (1988).